Generate Biomedicines Debuts with 6% Price Increase
Generate Biomedicines made its public debut last week. The clinical‑stage company, which positions itself as a pioneer in AI‑driven drug design and development, enters the market with a pitch that its generative biology platform can accelerate and broaden therapeutic discovery.LATEST IPOS AND DIRECT LISTINGS:Generate Biomedicinesopened on February 27 at $15.00. The company priced 25M shares at $16.00. The deal priced at the midpoint of the $15.00-$17.00 target range. Generate Biomedicines is a clinical-stage generative biology company that says it is "pioneering the AI revolution in biotechnology and drug design and development."RECENT SPAC IPOS:Fortress Value Acquisition Vopened on February 26 at $10, after it priced its initial public offering of 25M Class A ordinary shares at a price of $10.00 per share.APEX Tech Acquisitionopened on February 26 at $9.98, after it priced its initial public offering of 10M units at an offering price of $10.00 per unit, with each unit consisting of one ordinary share and one right to receive one-fourth of one ordinary share upon the consummation of an initial business combination.MOZAYYX Acquisitionopened on February 25 at $9.96, after it priced its upsized initial public offering of 26.1M units at $10.00 per unit.ClearThink 1 Acquisitionopened on February 24 at $9.95, after it priced its initial public offering of 12.5M units at $10.00 per unit.PERFORMANCE:Price as of 11:00 am ET on Monday, March 2 -Generate Biomedicines – up over 6% at $13.48.RECENT IPOS TO WATCH:Forgent Power Solutions, Eikon Therapeutics, Bob's Discount Furniture, and Veradermicsare already seeing coverage roll out, while SpyGlass Pharma, Agomaband Once Upon A Farmare among stocks that could see new coverage this week as the quiet periods for banks that underwrote the companies' IPOs expire.UPCOMING IPOS:Upcoming IPO and direct listings expected include Liftoff, Cerebras Systems, ayPay, and OpenAI.Clickto see upcoming IPO calendar on TipRanks.Liftoff Mobile- The company announced that it has confidentially submitted a draft registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock. The total number of shares to be offered and the price range for the proposed offering have not yet been determined. The offering is subject to market and other conditions and the completion of the SEC's review process.Cerebras Systems– The company has filed confidentially for a U.S. initial public offering, The Information's Valida Pau and Katie Roof. The re-filing comes after a major sales pact with OpenAI, the authors note.PayPay Corporation- The company filed for an initial public offering of American depositary shares, or ADSs, and has applied to list the ADSs on the Nasdaq Global Select Market under the symbol "PAYP." The prospects filed with the SEC states, "As Japan's leading financial technology company, we are dedicated to our goal of becoming a digital finance platform for all... We launched this service in October 2018 and it rapidly expanded to become a nation-wide leading cashless payments ecosystem that had approximately 72 million PayPay registered users as of December 31, 2025, representing a penetration of 75% among 96 million smartphone users in Japan. With the acquisition of PayPay Card Corporation in October 2022, our platform evolved to a next-generation payments ecosystem, seamlessly integrating our code-based payment and credit card payment services through our PayPay app."OpenAI- The company is accelerating its plans for a public listing as rivalry with Anthropic intensifies, now planning on listing in Q4 of this year, Berber Jin, Corrie Driebusch, and Kate Clark of The Wall Street Journal. OpenAI is holding discussions with Wall Street banks about a potential initial public offering and has hired several executives to oversee its finance team, sources told the Journal.SpaceX- Elon Musk is targeting mid-June for the timing of SpaceX's initial public offering, IPO, Ivan Levingston, Stephen Morris, and Mercedes Ruehl of The Financial Times, citing five people familiar with the matter. The company is looking to raise $50B at a valuation of $1.5T, the sources added.Opening Day" is The Fly's recurring series of stories on the latest initial public offerings, their performance, and upcoming IPOs.
Trade with 70% Backtested Accuracy
Analyst Views on GENB
No data
About the author
Cathie Wood Continues to Add to Growth Stock Positions
- MercadoLibre Financial Analysis: MercadoLibre reported a 45% year-over-year increase in net revenue and financial income to $8.8 billion in Q4, yet its operating profit rose only 8% due to a 50% spike in operating expenses, resulting in net income falling short of Wall Street expectations for the third consecutive quarter, indicating pressure on profitability.
- Intellia Therapeutics Positive Development: Intellia Therapeutics' stock surged 12% after the FDA lifted the clinical hold on its investigational new drug application, although the shares remain below their October highs, reflecting a mix of market optimism and inherent risks regarding its future gene-editing therapies.
- Generate Biomedicines IPO Performance: Generate Biomedicines raised $400 million in its IPO but closed at $12.91 on its first trading day, down from its $16 offering price, indicating cautious market sentiment towards its AI-driven drug development approach, with Cathie Wood continuing to buy shares during this period.
- Market Competition and Investment Pressure: MercadoLibre faces competitive challenges in Brazil, compelling it to significantly lower minimum order requirements for free shipping; while its long-term investment strategy appears sound, the short-term decline in earnings expectations may adversely affect its stock performance.
February IPO Market Review and Outlook
- Strong Fundraising: In February, 13 IPOs raised a total of $4.4 billion, surpassing the historical average over the past decade, indicating sustained investor interest in new listings despite market volatility.
- Market Volatility Impact: Although IPO activity was robust at the beginning of February, concerns over AI disruption led to a sell-off in tech stocks mid-month, resulting in price cuts and postponements for some high-profile IPOs, reflecting market uncertainty.
- Return Performance: The average return for IPOs this month was 22%, with those raising over $100 million achieving an impressive 28%, suggesting that investors remain optimistic about growth potential in the biotech and consumer sectors.
- Optimistic Future Outlook: Despite a decline in new filing activity, stabilizing market conditions are expected to encourage a gradual increase in IPO issuance in March, particularly given the strong performance of recent listings.
Generate Biomedicines Announces IPO Terms for $400 Million Raise
- IPO Plans: Generate Biomedicines aims to raise $400 million by offering 25 million shares at a price range of $15 to $17, reflecting strong market interest in its innovative drug development.
- AI Platform Advantage: The company leverages its AI-driven Generate Platform to create a tightly integrated design-build-test-learn loop, aimed at generating proprietary, therapeutically relevant data and differentiated molecular solutions, enhancing R&D efficiency.
- Clinical Progress: Generate Biomedicines has successfully advanced three computationally engineered proteins into human clinical testing, with GB-0895, a long-acting monoclonal antibody for severe asthma, currently enrolling patients in pivotal Phase 3 trials, demonstrating its therapeutic potential.
- Financial Performance: Founded in 2018, the company reported $32 million in revenue for the 12 months ending December 31, 2025, showcasing its growth potential and market appeal in the biopharmaceutical sector.
Generate Biomedicines Plans $400 Million IPO Amid February Market Lull
- Fundraising Plan: Generate Biomedicines (GENB) is set to go public by the end of February, aiming to raise $400 million at a market cap of $2.2 billion, indicating strong potential in the biotech sector.
- Technological Edge: The company employs an AI-enabled platform to develop proprietary, therapeutically relevant data and molecular solutions, having successfully advanced three computationally engineered proteins into human clinical testing, showcasing its effective R&D capabilities.
- Clinical Progress: Its lead product, GB-0895, is currently enrolling patients in pivotal Phase 3 clinical trials for severe asthma, which, if successful, will significantly enhance the company's competitiveness in the biopharmaceutical market.
- Market Environment: Despite the typical February lull in the IPO market, Generate Biomedicines' listing plan continues to attract investor interest, expected to bolster confidence for subsequent biotech IPOs.
Generate Biomedicines Raises $400 Million in IPO for AI-Driven Therapies
- Significant Fundraising: Generate Biomedicines successfully raised $400 million by offering 25 million shares at $16 each, reflecting strong market confidence in its AI-driven therapies and providing ample funding for future R&D initiatives.
- Platform Advantage: The company's AI-enabled Generate Platform integrates design, build, test, and learn processes tightly, aiming to create proprietary, therapeutically relevant data and differentiated molecular solutions, thereby enhancing its competitive edge in the biopharmaceutical sector.
- Notable Clinical Progress: Generate Biomedicines has successfully advanced three computationally engineered proteins into human clinical testing, with GB-0895, a long-acting anti-thymic stromal lymphopoietin monoclonal antibody, currently enrolling patients in pivotal Phase 3 trials for severe asthma, showcasing its therapeutic potential.
- Clear Listing Plans: The company plans to list on Nasdaq under the symbol GENB, with joint bookrunners including Goldman Sachs, Morgan Stanley, Piper Sandler, Guggenheim Securities, and Cantor Fitzgerald, further enhancing its market recognition and investor confidence.
Cathie Wood Continues to Add to Growth Stock Positions
- MercadoLibre Financial Analysis: MercadoLibre reported a 45% year-over-year increase in net revenue and financial income to $8.8 billion in Q4, yet its operating profit rose only 8% due to a 50% spike in operating expenses, resulting in net income falling short of Wall Street expectations for the third consecutive quarter, indicating pressure on profitability.
- Intellia Therapeutics Positive Development: Intellia Therapeutics' stock surged 12% after the FDA lifted the clinical hold on its investigational new drug application, although the shares remain below their October highs, reflecting a mix of market optimism and inherent risks regarding its future gene-editing therapies.
- Generate Biomedicines IPO Performance: Generate Biomedicines raised $400 million in its IPO but closed at $12.91 on its first trading day, down from its $16 offering price, indicating cautious market sentiment towards its AI-driven drug development approach, with Cathie Wood continuing to buy shares during this period.
- Market Competition and Investment Pressure: MercadoLibre faces competitive challenges in Brazil, compelling it to significantly lower minimum order requirements for free shipping; while its long-term investment strategy appears sound, the short-term decline in earnings expectations may adversely affect its stock performance.
February IPO Market Review and Outlook
- Strong Fundraising: In February, 13 IPOs raised a total of $4.4 billion, surpassing the historical average over the past decade, indicating sustained investor interest in new listings despite market volatility.
- Market Volatility Impact: Although IPO activity was robust at the beginning of February, concerns over AI disruption led to a sell-off in tech stocks mid-month, resulting in price cuts and postponements for some high-profile IPOs, reflecting market uncertainty.
- Return Performance: The average return for IPOs this month was 22%, with those raising over $100 million achieving an impressive 28%, suggesting that investors remain optimistic about growth potential in the biotech and consumer sectors.
- Optimistic Future Outlook: Despite a decline in new filing activity, stabilizing market conditions are expected to encourage a gradual increase in IPO issuance in March, particularly given the strong performance of recent listings.
Generate Biomedicines Announces IPO Terms for $400 Million Raise
- IPO Plans: Generate Biomedicines aims to raise $400 million by offering 25 million shares at a price range of $15 to $17, reflecting strong market interest in its innovative drug development.
- AI Platform Advantage: The company leverages its AI-driven Generate Platform to create a tightly integrated design-build-test-learn loop, aimed at generating proprietary, therapeutically relevant data and differentiated molecular solutions, enhancing R&D efficiency.
- Clinical Progress: Generate Biomedicines has successfully advanced three computationally engineered proteins into human clinical testing, with GB-0895, a long-acting monoclonal antibody for severe asthma, currently enrolling patients in pivotal Phase 3 trials, demonstrating its therapeutic potential.
- Financial Performance: Founded in 2018, the company reported $32 million in revenue for the 12 months ending December 31, 2025, showcasing its growth potential and market appeal in the biopharmaceutical sector.
Generate Biomedicines Plans $400 Million IPO Amid February Market Lull
- Fundraising Plan: Generate Biomedicines (GENB) is set to go public by the end of February, aiming to raise $400 million at a market cap of $2.2 billion, indicating strong potential in the biotech sector.
- Technological Edge: The company employs an AI-enabled platform to develop proprietary, therapeutically relevant data and molecular solutions, having successfully advanced three computationally engineered proteins into human clinical testing, showcasing its effective R&D capabilities.
- Clinical Progress: Its lead product, GB-0895, is currently enrolling patients in pivotal Phase 3 clinical trials for severe asthma, which, if successful, will significantly enhance the company's competitiveness in the biopharmaceutical market.
- Market Environment: Despite the typical February lull in the IPO market, Generate Biomedicines' listing plan continues to attract investor interest, expected to bolster confidence for subsequent biotech IPOs.
Generate Biomedicines Raises $400 Million in IPO for AI-Driven Therapies
- Significant Fundraising: Generate Biomedicines successfully raised $400 million by offering 25 million shares at $16 each, reflecting strong market confidence in its AI-driven therapies and providing ample funding for future R&D initiatives.
- Platform Advantage: The company's AI-enabled Generate Platform integrates design, build, test, and learn processes tightly, aiming to create proprietary, therapeutically relevant data and differentiated molecular solutions, thereby enhancing its competitive edge in the biopharmaceutical sector.
- Notable Clinical Progress: Generate Biomedicines has successfully advanced three computationally engineered proteins into human clinical testing, with GB-0895, a long-acting anti-thymic stromal lymphopoietin monoclonal antibody, currently enrolling patients in pivotal Phase 3 trials for severe asthma, showcasing its therapeutic potential.
- Clear Listing Plans: The company plans to list on Nasdaq under the symbol GENB, with joint bookrunners including Goldman Sachs, Morgan Stanley, Piper Sandler, Guggenheim Securities, and Cantor Fitzgerald, further enhancing its market recognition and investor confidence.
